BPC-157 went mainstream, but the peptide conversation has moved on. Epithalon, thymalin, and skin/metabolism complexes are now being discussed by longevity physicians. Here's what each does and what the evidence actually supports.
When Bryan Johnson added peptides to the Immortals Rx platform, he wasn't talking primarily about BPC-157. The peptide conversation has moved significantly in 2026: tissue repair peptides like BPC-157 and TB-500 are now mainstream biohacking. The frontier discussion is about aging-specific peptides — compounds that target the thymus, telomere dynamics, and the fundamental rate of cellular aging rather than injury recovery.
Here is a clear overview of the most discussed longevity peptides in 2026, the evidence behind each, and how accessible they actually are.
Peptides are short amino acid chains that act as signaling molecules. The body uses thousands of peptides to regulate virtually every physiological process: hormone secretion, immune modulation, tissue growth, metabolism, and more. Synthetic peptide drugs mimic or amplify these endogenous signals.
The longevity appeal is mechanistic precision: rather than broad pharmacological effects (like most drugs), peptides aim to restore specific signaling pathways that decline with age. The thymus involutes (shrinks) after puberty; immune peptides aim to partially reverse that involution. Telomeres shorten with each cell division; telomerase-activating peptides theoretically slow that process. Cellular senescence accelerates with age; peptides that target senescent cell accumulation are under investigation.
The caveat is that peptide research is largely early-stage. Much of it originates from Soviet and Eastern European research programs in the 1970s–90s (particularly thymic and pineal peptides) where clinical standards differ from modern Western RCT requirements.
What it is: A tetrapeptide (Ala-Glu-Asp-Gly) isolated from the bovine pineal gland by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation. The biological rationale: it appears to stimulate telomerase activity, the enzyme that rebuilds telomere ends. Telomere length is associated with cellular aging and longevity.
The evidence: Khavinson's group published a series of trials in Soviet and post-Soviet journals showing that epithalon extended lifespan in rodents and fruit flies, reduced cancer incidence, improved circadian and melatonin regulation, and produced telomere lengthening in human blood cells in vitro. A small Russian open-label trial in elderly patients reported improvements in immune markers and telomere length.
The limitation: The human trials are small, mostly open-label, and published in journals not accessible to Western peer review. No placebo-controlled, double-blinded Western RCT has validated these findings. The mechanistic story (telomerase activation → longevity) is compelling but the telomere-longevity causation in humans is still debated.
Practical: Epithalon is available as a research peptide. Typical protocols involve intermittent use (10-day cycles 2–4 times per year). Not approved for human use by FDA; available in research-peptide form.
What it is: A thymic peptide extract developed by Khavinson's group in the same era. The thymus gland produces T-cells and peaks in size around puberty, then involutes progressively. By age 70, thymic output of naïve T-cells is severely reduced — a key driver of immunosenescence. Thymalin aims to partially restore thymic output and immune competence.
The evidence: Khavinson published a 6-year longitudinal study in Russian geriatric patients showing reduced mortality in the thymalin group versus controls, improved immunity, and better functional status. The TRIIM trial (Greg Fahy's thymus rejuvenation study using HGH + DHEA + metformin) showed partial thymus regeneration and epigenetic age reversal in a small pilot study — validating the thymic rejuvenation concept in a Western setting, though not using thymalin specifically.
Practical: Thymalin is not widely available in Western markets. Thymic alpha-1 (thymosin alpha-1, Zadaxin) is an FDA-approved drug for hepatitis B and cancer immune adjuvant use, available in some countries OTC. Thymosin beta-4 fragment (TB-500) is the most accessible thymic-derived peptide in the supplement/research market.
What it is: A naturally occurring copper tripeptide (Gly-His-Lys-Cu) found in human plasma, saliva, and urine. It declines with age (from ~200 ng/mL at 20 to ~80 ng/mL at 60). Functions as a wound-healing signal, tissue remodeling regulator, and antioxidant.
The evidence: GHK-Cu has substantial in vitro and animal evidence for skin regeneration (stimulates collagen synthesis, fibroblast proliferation), wound healing acceleration, anti-inflammatory effects, and — intriguingly — gene expression effects that partially overlap with those seen in caloric restriction. A 2019 bioinformatics analysis found GHK-Cu gene signature similarities to longevity-associated gene expression profiles.
Practical: Topical GHK-Cu is widely available in skincare products (cosmetic use is established with real human skin data). Systemic GHK-Cu via subcutaneous injection is used in research settings. It is one of the more accessible peptides in the longevity stack: topical use for skin, with systemic use for those working with compounding physicians.
What it is: A melanocortin receptor agonist approved by the FDA for hypoactive sexual desire disorder (HSDD) in women (brand name Vyleesi). In longevity contexts, it's discussed for sexual health optimization, which declines significantly with age.
The evidence: FDA approval for HSDD is the most rigorous validation. Multiple RCTs confirm efficacy for sexual desire and arousal in premenopausal women. Some practitioners use it off-label in men for similar indications. The melanocortin system has broader effects on energy balance, inflammation, and neural function.
For most people, the accessible peptide longevity stack focuses on the compounds with the best combination of evidence and availability:
1. BPC-157 (oral capsules, available OTC as research product): Best evidence for tissue repair, gut healing. See the BPC-157 evidence review for the full breakdown.
2. GHK-Cu (topical, widely available): Established skin regeneration evidence; systemic use via compounding physicians for those wanting broader effects.
3. Collagen peptides (oral, mainstream supplement): Bioavailable amino acid precursors that support collagen synthesis systemically. Not a signaling peptide but a building-block approach to peptide nutrition.
The longevity peptide space is more exciting — and more preliminary — than the tissue-repair peptide space that BPC-157 occupies. Epithalon and thymalin have mechanistically interesting, biologically plausible effects on fundamental aging processes. The evidence base is real but comes from research traditions that don't meet modern Western RCT standards.
The practical hierarchy: GHK-Cu topically for skin (strong cosmetic evidence), collagen peptides orally (solid RCT data), BPC-157 for tissue repair (strong animal data, limited human trials), and the aging-specific peptides (epithalon, thymalin) for those working with longevity physicians who can provide proper compounding and monitoring.
The mainstreaming of peptide therapy via platforms like Immortals Rx will accelerate clinical experience and eventually produce better human data. For now, the most responsible approach is evidence-informed enthusiasm: engaging with the promising mechanisms while being honest about the evidence gaps.